ArticleScientific reports2025
Determinants of loss to follow-up among women on option B + in Southern Ethiopia, 2014-2022: a cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization has realized Option B + program to ensure lifelong antiretroviral therapy for all women with human immunodeficiency virus to eradicate the vertical transmission of the virus. The Option B + program is expected to achieve the United Nations target of 95% retention in care by 2025. Despite the successful implementation of Option B + in southern Ethiopia for the past nine years, the issue of loss to follow-up continues to be a major challenge. Thus, this study aims to examine the incidence and determinants of loss to follow-up in women under the Option B + program in southern Ethiopia from 2014 to 2022. A retrospective cohort study was conducted, and data were collected using a structured checklist from 468 charts of women on Option B+, of which 441 were included in the final analysis. The Kaplan-Meier survival curve with the Log-rank test was used to estimate the survival time. Bivariable and multivariable Cox proportional hazard regression models were fitted to identify determinants of loss to follow-up. Overall, 17.5% of women were lost to follow-up during the entire observation period, resulting in 5.9 new cases per 1000 women in one month (95% CI: 4.8-7.5). The cumulative probability of loss to follow-ups increased over time, from 2.7% at 6 months to 4.2% at 12 months, and peaked at 43.4% at 60 months. The multivariable Cox regression results revealed that women at a higher risk of loss to follow-up were those who received antiretroviral therapy at health centers compared to those enrolled at hospitals, initiated antiretroviral therapy on the day of diagnosis compared to those who started later, had poor antiretroviral therapy adherence, and did not disclose their serostatus to anyone. The rate of loss to follow-up in southern Ethiopia is not on track to meet the United Nations target. Therefore, it is crucial to develop practical strategies for enhancing antiretroviral therapy adherence, considering individual factors for optimal treatment timing, evaluating the quality of health centers' antiretroviral therapy services, and addressing women's concerns about disclosure to minimize loss to follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.